NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1496.60 -13.10 (-0.87%)

1.0M NSE+BSE Volume

NSE 26 Sep, 2025 10:27 AM (IST)

120,890.2

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

06 Nov 2018

1496.60

-0.87%

Cipla (2QFY19): Hobbling with cost pressures. Maintain NEUTRAL

Neutral: Cipla Ltd.

Target

HDFC Securities

At CMP, valuations remain unsupportive (30/24x FY19E/20E EPS). Maintain NEUTRAL with a TP of Rs 605 (22x FY20E EPS). Cipla reported a disappointing set of numbers in 2QFY19 with revenue at Rs 40.1bn, down 2%YoY/ up 2%QoQ. The domestic business was flat YoY on a high base due to post-GST restocking, whereas US sales grew 12%YoY in constant currency to US$ 108mn led by new launches. Despite gross margin expanding 285/95bps YoY/QoQ to ~65%, increased R&D; spend, sales-linked costs and capacity issues led to a 220/95bps YoY/QoQ fall in EBITDA margin, now at 17.5%.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

06 Nov 2018

1496.60

-0.87%

Result Review of Cipla

Hold: Cipla Ltd.

Target

IDBI Capital

Cipla's Q2FY19 sales at Rs40bn were 3.6% above our expectations while EBITDA/PAT at Rs7bn/Rs3.8bn were 0.3%/12.5% below our expectations. Domestic business was down 0.1% YoY impacted by 1) higher base due to restocking post GST implementation and 2) Q2FY18 experienced a strong acute season while there is a delay during this season. We have revised upwards our USD currency estimates from 68 to 70 for FY19/20E, however, given concerns on sales pickup in 1) US, 2) Global API and 3) SAGA, we have revised downwards our sales estimates. We expect Cipla's sales/EBITDA/net profit to grow at a CAGR of 10.7%/17%/23.5%, respectively, over FY18-20E....

Cipla Ltd.'s price crossed below 100Day SMA today

Cipla Ltd.

06 Nov 2018

1496.60

-0.87%

Cipla

Hold: Cipla Ltd.

Target

ICICI Securities Limited

Cipla's Q2FY19 results were weaker-than-expected on the operational front. Revenues de-grew 1.7% YoY to | 4012 crore (Idirect estimate: | 4042.4 crore) mainly due to high base of restocking in the domestic market and a fall in the tender opportunity in South Africa and other emerging markets EBITDA margins contracted 220 bps YoY to 17.5% (I-direct estimate: 19.1%) due to higher other expenditure and employee cost. EBITDA de-grew 12.7% YoY to | 702.2 crore (I-direct estimate: | 771 crore) Net profit fell 15.6% YoY to | 356.8 crore (I-direct estimate: | 368.9...

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

28 Aug 2018

1496.60

-0.87%

CIPLA LTD

Hold: Cipla Ltd.

Target

Geojit BNP Paribas

Revenue growth led by improved India and SA performance Cipla reported 12% YoY growth in revenue in Q1FY19 on the back of continued strong growth across India (up 22% YoY), South Africa (up 23% YoY) and API business (up 54% YoY). The company highlighted that the growth in India business in Q2FY19 should be lower as compared to corresponding quarter last year due to high base on account of GST led re-stocking. The company's South Africa business delivered yet another strong quarter with a robust 23% YoY increase in revenue (15% in dollar terms), outperforming the market (7% in dollar terms) led by strong momentum in Sereflo Synchrobreathe which grew at 45% YoY. Going ahead, the company remains optimistic about the growth...

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla Ltd.

13 Aug 2018

1496.60

-0.87%

Cipla Ltd Q1FY19 results Comment

Results Update: Cipla Ltd.

HDFC Securities

Revenue rose by 10.01% to Rs. 3845.84 Cr in Q1FY19 when compared to the previous quarter. Cipla Ltd Q1FY19 results Comment

Cipla Ltd. is trading below its 30 day SMA of 1563.9

Cipla Ltd.

11 Aug 2018

1496.60

-0.87%

Result Review of Cipla

Hold: Cipla Ltd.

Target

IDBI Capital

We expect domestic growth to be in-line with the industry, while the US business to increase its contribution going forward. One specialty product launch in US every quarter to support better overall margins. Since the US sales is ~USD100mn lower than expectations, we are slightly tapering down our sales forecasts for FY19/20. We have reduced the run-rate of depreciation which has resulted in our EPS to increase by 17% for FY19 and 6.3% in FY20.expect Cipla's sales/EBITDA/net profit to grow at a CAGR of 12.5%/19%/31.7%, respectively, over FY18-20E. US growth the key for improvement in the EBITDA margins: Cipla continues to have...

Cipla Ltd.'s price crossed below 100Day SMA today

Cipla Ltd.

10 Aug 2018

1496.60

-0.87%

Cipla - 1QFY19 Result Update

Buy: Cipla Ltd.

Recommendation Target

Reliance Securities

Positive Outlook on India & US Biz; Upgrade to BUY ff South Africa Biz (15% of Sales): Adjusted for discontinuation of Animal Health business, South African business grew by 14% YoY (vs. 7% market growth). It plans to launch Filgrastim...

Cipla Ltd. is trading below its 30 day SMA of 1563.9

Cipla Ltd.

09 Aug 2018

1496.60

-0.87%

Cipla (1QFY19): Resilient performance. Maintain NEUTRAL

Neutral: Cipla Ltd.

Target

HDFC Securities

At CMP, valuations remain unsupportive (29x FY19E and 23x FY20E EPS). Maintain NEUTRAL with a TP of Rs 595 (22x FY20E). Ciplas top line at Rs 39.4bn grew 11.7%YoY and 6.5%QoQ with India and the US business growing 21.5% and 3.7% YoY respectively. EBITDA was Rs 7.3bn, up 12.4% YoY. The margin was 18.4%, flat YoY/up 338bpsQoQ, led by favourable business mix. However, it was 200bps below our estimates as 1Q has always been a good quarter for Cipla owing to its domestic acute portfolio.

Cipla Ltd. is trading below its 30 day SMA of 1563.9

Cipla Ltd.

09 Aug 2018

1496.60

-0.87%

Cipla

Hold: Cipla Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 11.7% YoY to | 3939 crore (I-direct estimate: | 4137.2 crore) due to 21.5% YoY growth in India to | 1544 crore (Idirect estimate: | 1588.8 crore) and 17.8% YoY growth in South Africa to | 575 crore (I-direct estimate: | 585.6 crore). US revenues grew 3.7% YoY to | 670 crore (I-direct estimate: | 750.4 crore) EBITDA margins improved 10 bps YoY to 18.4% but came in lower than I-direct estimate of 20.3% due lower gross margins (63.9% against I-direct estimates of 66.6%)...

Cipla Ltd. has an average target of 1702.60 from 10 brokers.

Is Cipla Ltd. worth buying?

624 Votes:

Buy 75.8%

Sell 13.94%

Hold 10.26%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf